Stock of ImmunityBio, Inc. (IBRX) is climbing about 19 percent during Wednesday morning trading after the company announced that the European Commission has granted conditional marketing authorization for ANKTIVA in combination with Bacillus Calmette-Guérin for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
The company's shares are currently trading at $7.17 on the Nasdaq, up 19.20 percent. The stock opened at $6.06 and has climbed as high as $7.15 so far in today's session. Over the past year, it has traded in a range of $1.83 to $8.26.
With this authorization, ANKTIVA is now approved in 33 countries spanning four regulatory jurisdictions, establishing a global commercial footprint in under two years from initial U.S. Food and Drug Administration approval, the company noted.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.